Popular Articles

Meda: FDA Approval For Onsolis Anticipated During Summer 2009
Since August 2008, Meda (STO:MEDAA) and BioDelivery Sciences International (BDSI) have worked in close collaboration with the U.S. Food and Drug Administration (FDA) to complete the final requirement of a Risk Evaluation and Mitigation Strategy (REMS) program for Onsolis (fentanyl - treatment of breakthrough cancer pain).
pharmacy online
Intestinal Inflammation Linked To Systemic Chromosome Damage
UCLA scientists have linked for the first time intestinal inflammation with systemic chromosome damage in mice, a finding that may lead to the early identification and treatment of human inflammatory disorders, some of which increase risk for several types of cancer.
News of the day
Agios Pharmaceuticals' Focus Of Drug Research - Cancer Metabolism - Selected For Stand Up To Cancer Grant
Agios Pharmaceuticals today announced that Stand Up To Cancer (SU2C), a charitable initiative for new cancer treatments, has selected the Cancer Metabolism "dream team" led by Agios founder Dr. Craig Thompson and including Agios advisors Drs. Chi Dang and Joshua Rabinowitz. Cancer Metabolism is one of only five research areas chosen to share in $73.6 million in translational research funding, based on a rigorous selection process by independent scientific advisors assembled by SU2C"s scientific partner, the American Association for Cancer Research (AACR). Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. This new understanding of a fundamental mechanism of cancer represents a powerful Achilles" heel to target this deadly disease.
Sexual Health

Award For Pioneering Stem Cell Research To Mend Broken Bones

Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing. Nearly ÷£4M has been awarded to scientists from the universities of Keele, Imperial College London, Nottingham and Southampton and who will work together combining stem cell science and tissue engineering to look at the development and repair of human skeletal tissue. Fractures, bone loss due to trauma or disease and other orthopaedic conditions pose a significant clinical and socioeconomic problem, especially with an aging population, but as yet there is no large scale effective treatment for replacing or repairing damaged bones. Professor Richard Oreffo, from the University of Southampton who is leading the study, said: "Despite intense research, significant challenges for the reconstruction of tissues such as bone remain. Bone and cartilage tissue repair is a highly complex development process. A key requirement for these regeneration strategies to succeed remains our ability to understand skeletal cell activity, develop appropriate scaffolds and to understand how the environment the cells find themselves in affects their ability to interact with other cells to form new bone or cartilage." Over the next five years, the scientists will combine their expertise in skeletal stem cells, scaffolds and materials chemistry to identify the key growth factors, matrix proteins and physical conditions that will enhance tissue regeneration and ultimately lead to more effective skeletal repair strategies. "We believe a paradigm shift in approach is required if we are to lead internationally in regenerative medicine. Our findings of how stem cells, scaffolds and the physical environment can be combined to induce new bone and cartilage will be used to augment and accelerate bone repair. This will allow us to develop new regimes for cartilage and bone regeneration ultimately leading to more effective treatments" explained Professor Oreffo. The research consortium comprises Professor Alicia El Haj, Keele University, Professor Molly Stevens, Imperial College London, Professor Kevin Shakesheff, University of Nottingham and Professor Richard Oreffo, University of Southampton. Commenting on the award, Professor Douglas Kell, BBSRC Chief Executive said: "Fractures, particularly among older people, are a major cause of morbidly and mortality, and costs the NHS billions of pounds each year. This truly multidisciplinary approach to the basic research necessary to improve our scientific understanding opens up exciting possibilities in the area of skeletal development and repair, an area where advancement is becoming increasingly urgent on both a quality of life and an economic level as our population gets older." BBSRC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):